{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:42:58Z","timestamp":1782139378377,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CSL Behring Canada Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Evidence linking hereditary angioedema (HAE) to the potential association of developing other comorbidities, and how it is affected by HAE treatment is needed. The objective of this study is to identify comorbidities and measure the prevalence in HAE patients, compared to the prevalence in the general population using multiple Canadian sources when available.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A quantitative survey design via a self-administered anonymous online questionnaire was conducted from October 13, 2022, to January 11, 2023. Respondents were individuals with HAE, enrolled in the CSL Behring patient support program (CSL Behring PLUS+; PSP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study included 123 patients (81% female; 60% HAE-1\/HAE-2, 24% HAE Normal C1-INH (nC1-INH), 16% unsure of HAE type; 85% of patients were on long-term prophylaxis plus on-demand). Patients reported using the following HAE treatments: C1-esterase inhibitor (subcutaneous or intravenous), lanadelumab, icatibant, danazol, and tranexamic acid. Respondents (69%) reported at least one: autoimmune condition, asthma, or allergy. Reported autoimmune conditions (psoriasis, rheumatoid arthritis, inflammatory bowel disease, chronic urticaria, lupus, and psoriatic arthritis) were much higher than the general population (31% versus 5\u20138%). Patient-reported allergies were two times higher than the general population (54% versus 27%; i.e., aeroallergens) and asthma rates nearly two times higher than the general population (17% versus 8\u201311%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This cohort of HAE patients, most of whom were on prophylaxis, reported an increased prevalence of certain comorbidities compared to the general Canadian population. Healthcare professionals should be aware of the potentially increased risk of autoimmune conditions, allergies, and asthma in patients with HAE.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13223-025-00953-8","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:03:20Z","timestamp":1742400200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study"],"prefix":"10.1186","volume":"21","author":[{"given":"Paul K.","family":"Keith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lacuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Dansereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Tanios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"El-Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maye","family":"Machnouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hachem","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Waserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"1","key":"953_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13023-018-0815-5","volume":"13","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Magerl M, Maetzel A, Maurer M. Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13(1):73.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"953_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-021-01717-4","volume":"16","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Murphy R, de la Cruz M, Janssen E, Boysen HB, Jain G, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16(1):94.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"953_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/rth2.12175","volume":"3","author":"M Levi","year":"2018","unstructured":"Levi M, Cohn DM, Zeerleder S. Hereditary Angioedema: linking complement regulation to the coagulation system. Res Pract Thromb Haemost. 2018;3(1):38\u201343.","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"953_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","volume":"80","author":"HJ Longhurst","year":"2019","unstructured":"Longhurst HJ, Bork K. Hereditary Angioedema: an update on causes, manifestations and treatment. Br J Hosp Med. 2019;80(7):391\u20138.","journal-title":"Br J Hosp Med"},{"issue":"6","key":"953_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2340\/00015555-2014","volume":"95","author":"A Bygum","year":"2015","unstructured":"Bygum A, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Beusterien K, Hautamaki E, Sisic Z, Wait S, et al. Burden of illness in Hereditary Angioedema: a conceptual model. Acta Dermato-Venereologica. 2015;95(6):706\u201310.","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"953_CR6","doi-asserted-by":"publisher","first-page":"e0199305","DOI":"10.1371\/journal.pone.0199305","volume":"13","author":"I Liesmaa","year":"2018","unstructured":"Liesmaa I, Paakkanen R, J\u00e4rvinen A, Valtonen V, Lokki ML. Clinical features of patients with homozygous complement C4A or C4B deficiency. PLoS ONE. 2018;13(6):e0199305.","journal-title":"PLoS ONE"},{"issue":"3","key":"953_CR7","doi-asserted-by":"publisher","first-page":"e12135","DOI":"10.1002\/clt2.12135","volume":"12","author":"LS Bj\u00f6rkman","year":"2022","unstructured":"Bj\u00f6rkman LS, Persson B, Aronsson D, Skattum L, Nordenfelt P, Egesten A. Comorbidities in hereditary angioedema\u2014A population-based cohort study. Clin Transl Allergy. 2022;12(3):e12135.","journal-title":"Clin Transl Allergy"},{"key":"953_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13223-020-00437-x","volume":"16","author":"D Levy","year":"2020","unstructured":"Levy D, Craig T, Keith PK, Krishnarajah G, Beckerman R, Prusty S. Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review. Allergy Asthma Clin Immunol. 2020;16:41.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"953_CR9","doi-asserted-by":"crossref","unstructured":"Betschel S, Badiou J, Binkley K, Borici-Mazi R, H\u00e9bert J, Kanani A, et al. International\/Canadian Hereditary Angioedema Guideline Allergy Asthma Clin Immunol. 2019;15(1):72.","DOI":"10.1186\/s13223-019-0376-8"},{"key":"953_CR10","doi-asserted-by":"publisher","first-page":"694928","DOI":"10.3389\/fimmu.2021.694928","volume":"12","author":"H Wang","year":"2021","unstructured":"Wang H, Liu M. Complement C4, infections, and Autoimmune diseases. Front Immunol. 2021;12:694928.","journal-title":"Front Immunol"},{"issue":"3","key":"953_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.7326\/0003-4819-86-3-312","volume":"86","author":"VH Donaldson","year":"1977","unstructured":"Donaldson VH, Hess EV, Mcadams AJ. Lupus-Erythematosus-Like Disease in three unrelated women with Hereditary Angioneurotic Edema. Ann Intern Med. 1977;86(3):312\u20133.","journal-title":"Ann Intern Med"},{"issue":"5","key":"953_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/0091-6749(86)90424-0","volume":"77","author":"CM Brickman","year":"1986","unstructured":"Brickman CM, Tsokos GC, Balow JE, Lawley TJ, Santaella M, Hammer CH, et al. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol. 1986;77(5):749\u201357.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"953_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.autrev.2015.02.001","volume":"14","author":"I Gallais S\u00e9r\u00e9zal","year":"2015","unstructured":"Gallais S\u00e9r\u00e9zal I, Bouillet L, Dh\u00f4te R, Gayet S, Jeandel PY, Blanchard-Delaunay C, et al. Hereditary Angioedema and lupus: a French retrospective study and literature review. Autoimmun rev. 2015;14(6):564\u20138.","journal-title":"Autoimmun rev"},{"issue":"1","key":"953_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clim.2006.09.015","volume":"123","author":"S Khan","year":"2007","unstructured":"Khan S, Tarzi MD, Dor\u00e9 PC, Sewell WAC, Longhurst HJ. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema. Clin Immunol. 2007;123(1):14\u20137.","journal-title":"Clin Immunol"},{"issue":"5","key":"953_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/jcp.40.5.518","volume":"40","author":"MF Muhlemann","year":"1987","unstructured":"Muhlemann MF, Macrae KD, Smith AM, Beck P, Hine I, Hegde U, et al. Hereditary Angioedema and thyroid autoimmunity. J Clin Pathol. 1987;40(5):518\u201323.","journal-title":"J Clin Pathol"},{"key":"953_CR16","unstructured":"Qualtrics International Inc. Qualtrics XM \/. \/ The Leading Experience Management Software [Internet]. [cited 2023 Nov 25]. Available from: https:\/\/www.qualtrics.com\/en-au\/"},{"key":"953_CR17","unstructured":"The Analytical Group Inc. WinCross Desktop 20 [Internet]. [cited 2023 Nov 25]. Available from: https:\/\/www.analyticalgroup.com\/WinCross.html"},{"key":"953_CR18","unstructured":"Statistics Canada. Chronic Conditions, 2017 [Internet]. Government of Canada; 2018 Nov [cited 2023 Nov 25]. Available from: https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-625-x\/2018001\/article\/54983-eng.htm"},{"key":"953_CR19","unstructured":"Statistics Canada. Survey on COVID-19 and Mental Health, February to May 2021 [Internet]. Government of Canada; 2021 Sep [cited 2023 Nov 25]. (The Daily). Available from: https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/210927\/dq210927a-eng.htm"},{"key":"953_CR20","unstructured":"Statistics Canada. Blood pressure of adults, 2016\u20132019 [Internet]. Government of Canada; 2021 Mar [cited 2023 Nov 25]. Available from: https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-625-x\/2021001\/article\/00001-eng.htm"},{"key":"953_CR21","unstructured":"National Stem Cell Foundation. Autoimmune Disease [Internet]. National Stem Cell Foundation. [cited 2023 Nov 25]. Available from: https:\/\/nationalstemcellfoundation.org\/glossary\/autoimmune-disease\/"},{"issue":"3","key":"953_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-021-00518-8","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, Gniadecki R, Beecker J, Dutz J, Gooderham MJ, Hong CH, et al. Psoriasis Prevalence and Severity by Expert Elicitation. Dermatol Ther (Heidelb). 2021;11(3):1053\u201364.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"953_CR23","unstructured":"Public Health Agency of Canada. Rheumatoid arthritis in Canada [Internet]. Government of Canada; 2020 Sep [cited 2023 Nov 25]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/rheumatoid-arthritis.html"},{"issue":"Suppl 2","key":"953_CR24","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1093\/jcag\/gwad004","volume":"6","author":"S Coward","year":"2023","unstructured":"Coward S, Benchimol EI, Kuenzig ME, Windsor JW, Bernstein CN, Bitton A, et al. The 2023 impact of inflammatory bowel disease in Canada: epidemiology of IBD. J Can Assoc Gastroenterol. 2023;6(Suppl 2):S9\u201315.","journal-title":"J Can Assoc Gastroenterol"},{"issue":"1","key":"953_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13223-015-0072-2","volume":"11","author":"G Sussman","year":"2015","unstructured":"Sussman G, H\u00e9bert J, Gulliver W, Lynde C, Waserman S, Kanani A, et al. Insights and advances in chronic urticaria: a Canadian perspective. Allergy Asthma Clin Immunol. 2015;11(1):7.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"953_CR26","unstructured":"Lupus Canada. What is Lupus?| Lupus Canada [Internet]. 2020 [cited 2023 Nov 25]. Available from: https:\/\/www.lupuscanada.org\/living-with-lupus\/what-is-lupus\/"},{"key":"953_CR27","unstructured":"Arthritis Society Canada. Psoriatic Arthritis - Symptoms, Causes, Diagnosis & Treatments [Internet]. [cited 2023 Nov 25]. Available from: https:\/\/arthritis.ca\/about-arthritis\/arthritis-types-(a-z)\/types\/psoriatic-arthritis"},{"issue":"4","key":"953_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The Epidemiology Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"key":"953_CR29","unstructured":"Statistics Canada. Asthma, by age group [Internet]. Government of Canada; 2017 Mar [cited 2023 Dec 1]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310009608"},{"issue":"3","key":"953_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.46747\/cfp.6703187","volume":"67","author":"PD St John","year":"2021","unstructured":"St John PD, Menec V, Tyas SL, Tate R, Griffith L. Multimorbidity in canadians living in the community. Can Fam Physician. 2021;67(3):187\u201397.","journal-title":"Can Fam Physician"},{"key":"953_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13223-020-00439-9","volume":"16","author":"H Farkas","year":"2020","unstructured":"Farkas H, Levy D, Supina D, Berger M, Prusty S, Fridman M. Hereditary Angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database. Allergy Asthma Clin Immunol. 2020;16:42.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"953_CR32","doi-asserted-by":"publisher","first-page":"AB102","DOI":"10.1016\/j.jaci.2019.12.621","volume":"145","author":"R Tachdjian","year":"2020","unstructured":"Tachdjian R, Borra S, Shrestha S, Wang L, Chiao J, Supina D, et al. Burden of Autoimmune disorders among patients with Hereditary Angioedema in the United States. J Allergy Clin Immunol. 2020;145(2):AB102.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"953_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.autrev.2015.03.006","volume":"14","author":"P Triggianese","year":"2015","unstructured":"Triggianese P, Chimenti MS, Toubi E, Ballanti E, Guarino MD, Perricone C, et al. The autoimmune side of hereditary angioedema: insights on the pathogenesis. Autoimmun rev. 2015;14(8):665\u20139.","journal-title":"Autoimmun rev"},{"issue":"3","key":"953_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/0091-6749(86)90037-0","volume":"78","author":"R D\u2019Amelio","year":"1986","unstructured":"D\u2019Amelio R, Perricone R, De Carolis C, Pontesilli O, Matricardi PM, Fontana L. Immune complexes in hereditary angioneurotic edema (HANE) - ScienceDirect. J Allergy Clin Immunol. 1986;78(3):486\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"953_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.anai.2012.10.008","volume":"109","author":"DM Lang","year":"2012","unstructured":"Lang DM, Aberer W, Bernstein JA, Chng HH, Grumach AS, Hide M, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012;109(6):395\u2013402.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"953_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","volume":"17","author":"K Bork","year":"2021","unstructured":"Bork K, Anderson JT, Caballero T, Craig T, Johnston DT, Li HH, et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021;17(1):40.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"953_CR37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2105\/AJPH.2011.300423","volume":"102","author":"JM Hootman","year":"2012","unstructured":"Hootman JM, Helmick CG, Brady TJ. A Public Health Approach to addressing arthritis in older adults: the most common cause of disability. Am J Public Health. 2012;102(3):426\u201333.","journal-title":"Am J Public Health"},{"issue":"3","key":"953_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.dhjo.2019.03.001","volume":"12","author":"KA Theis","year":"2019","unstructured":"Theis KA, Steinweg A, Helmick CG, Courtney-Long E, Bolen JA, Lee R. Which one? What kind? How many? Types, causes, and prevalence of disability among U.S. adults. Disabil Health J. 2019;12(3):411\u201321.","journal-title":"Disabil Health J"},{"key":"953_CR39","doi-asserted-by":"crossref","unstructured":"Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The prevalence of Autoimmune disorders in women: a narrative review. Cureus. 2020;12(5):e8094.","DOI":"10.7759\/cureus.8094"},{"issue":"4","key":"953_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.anai.2016.08.014","volume":"117","author":"A Zanichelli","year":"2016","unstructured":"Zanichelli A, Longhurst HJ, Maurer M, Bouillet L, Aberer W, Fabien V, et al. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann Allergy Asthma Immunol. 2016;117(4):394\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"953_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.anai.2023.03.005","volume":"130","author":"JA Meadows","year":"2023","unstructured":"Meadows JA, Anderson J, Gower RG. Challenges in the management of hereditary angioedema in urban and rural settings. Ann Allergy Asthma Immunol. 2023;130(6):760\u2013e7673.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"953_CR42","doi-asserted-by":"publisher","first-page":"953117","DOI":"10.3389\/falgy.2022.953117","volume":"3","author":"JCY Wong","year":"2022","unstructured":"Wong JCY, Cheong N, Lau CS, Li PH. Prevalence and impact of misdiagnosed drug allergy labels among patients with hereditary angioedema. Front Allergy. 2022;3:953117.","journal-title":"Front Allergy"},{"issue":"1","key":"953_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04139.x","volume":"160","author":"H Okada","year":"2010","unstructured":"Okada H, Kuhn C, Feillet H, Bach JF. The \u2018hygiene hypothesis\u2019 for autoimmune and allergic diseases: an update. Clin Exp Immunol. 2010;160(1):1\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"953_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2249.2008.03679.x","volume":"153","author":"RL Rabin","year":"2008","unstructured":"Rabin RL, Levinson AI. The nexus between atopic disease and autoimmunity: a review of the epidemiological and mechanistic literature. Clin Exp Immunol. 2008;153(1):19\u201330.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"953_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1586\/1744666X.4.6.767","volume":"4","author":"A Tedeschi","year":"2008","unstructured":"Tedeschi A, Asero R. Asthma and autoimmunity: a complex but intriguing relation. Expert Rev Clin Immunol. 2008;4(6):767\u201376.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"953_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4168\/aair.2018.10.5.428","volume":"10","author":"M Mukherjee","year":"2018","unstructured":"Mukherjee M, Nair P. Autoimmune responses in severe asthma. Allergy Asthma Immunol Res. 2018;10(5):428.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"4","key":"953_CR47","first-page":"416","volume":"17","author":"C Sch\u00f6ffl","year":"2019","unstructured":"Sch\u00f6ffl C, Wiednig M, Koch L, Blagojevic D, Duschet P, Hawranek T, et al. Hereditary Angioedema in Austria: prevalence and regional peculiarities. JDDG: J Der Deutschen Dermatologischen Gesellschaft. 2019;17(4):416\u201323.","journal-title":"JDDG: J Der Deutschen Dermatologischen Gesellschaft"},{"issue":"1","key":"953_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1710-1492-9-29","volume":"9","author":"A Zanichelli","year":"2013","unstructured":"Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M. Hereditary Angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol. 2013;9(1):29.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"953_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.alit.2020.09.008","volume":"70","author":"K Iwamoto","year":"2021","unstructured":"Iwamoto K, Yamamoto B, Ohsawa I, Honda D, Horiuchi T, Tanaka A, et al. The diagnosis and treatment of hereditary angioedema patients in Japan: a patient reported outcome survey. Allergology Int. 2021;70(2):235\u201343.","journal-title":"Allergology Int"},{"issue":"9","key":"953_CR50","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1159\/000514973","volume":"182","author":"J Zarnowski","year":"2021","unstructured":"Zarnowski J, Rabe M, Kage P, Simon JC, Treudler R. Prophylactic treatment in Hereditary Angioedema is Associated with reduced anxiety in patients in Leipzig, Germany. Int Arch Allergy Immunol. 2021;182(9):819\u201326.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"953_CR51","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"953_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13223-023-00795-2","volume":"19","author":"J Mendivil","year":"2023","unstructured":"Mendivil J, DerSarkissian M, Banerji A, Diwakar L, Katelaris CH, Keith PK, et al. A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis. Allergy Asthma Clin Immunol. 2023;19(1):48.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"953_CR53","unstructured":"Lumry WR, Settipane RA. Hereditary angioedema: Epidemiology and burden of disease [Internet]. OceanSide Publications, Inc; 2020 [cited 2023 Nov 26]. Available from: https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/a00106s1\/art00003;jsessionid=17ry4cbcmc1r1.x-ic-live-01"},{"issue":"1","key":"953_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13223-021-00621-7","volume":"17","author":"P Stepaniuk","year":"2021","unstructured":"Stepaniuk P, Kanani A. Malignancy and immune disorders in patients with hereditary angioedema. Allergy Asthma Clin Immunol. 2021;17(1):134.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"953_CR55","doi-asserted-by":"crossref","unstructured":"Zuraw BL, Hereditary Angioedema. NEJM. 2008;359:1027\u201336.","DOI":"10.1056\/NEJMcp0803977"},{"key":"953_CR56","doi-asserted-by":"crossref","unstructured":"Bernstein JA. HAE Update: Epidemiology and burden of disease. allergy asthma proc. 2013;34(1):3\u20136.","DOI":"10.2500\/aap.2013.34.3623"},{"key":"953_CR57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/JAA.S396338","volume":"16","author":"HJ Longhurst","year":"2023","unstructured":"Longhurst HJ, Valerieva A. A review of Randomized controlled trials of Hereditary Angioedema Long-Term Prophylaxis with C1 inhibitor replacement therapy: alleviation of disease symptoms is Achievable. J Asthma Allergy. 2023;16:269\u201377.","journal-title":"J Asthma Allergy"},{"issue":"2","key":"953_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12016-018-8684-1","volume":"56","author":"H Li","year":"2019","unstructured":"Li H, Riedl M, Kashkin J. Update on the Use of C1-Esterase inhibitor replacement therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. Clin Rev Allerg Immunol. 2019;56(2):207\u201318.","journal-title":"Clin Rev Allerg Immunol"},{"issue":"3","key":"953_CR59","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.anai.2020.05.015","volume":"125","author":"JA Bernstein","year":"2020","unstructured":"Bernstein JA, Schwartz L, Yang W, Baker J, Anderson J, Farkas H, et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2020;125(3):334\u2013e3401.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-00953-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-025-00953-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-00953-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T22:20:48Z","timestamp":1742422848000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-025-00953-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1186\/s13223-025-00953-8","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Health Ethics Research Board at Advarra.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PKK: has been a speaker, advisory board member, or consultant for and has received honoraria from ALK- Abell\u00f3, AstraZeneca, Bausch, Bayer, BioCryst Pharmaceuticals, Canadian Agency for Drugs and Technologies in Health (CADTH), Canadian Pharmacists Association (CPA), CSL Behring, GSK, Medexus Pharmaceuticals Inc., Merck & Co., Novartis, Sanofi Genzyme, Takeda\/Shire, and Valeo; has received research grants from CSL Behring and Takeda\/Shire; serves as a medical advisor (volunteer) for Hereditary Angioedema Canada, a patient organisation; serves as a board member (volunteer) for the Canadian Hereditary Angioedema Network (CHAEN), a physician organisation; and is an employee of McMaster University; GL: has received consultancy and speaker fees from Takeda, CSL Behring, and consultancy fees from BioCryst, KalVista, and is a member of CHAEN; DG: has consulted and participated in advisory boards and has received honoraria from BioCryst, CSL Behring, and Takeda; SDB: has consulted and participated in advisory boards for ALK, Astria, BioCryst Pharmaceuticals, Canadian Blood Services, CSL Behring, Ionis Pharmaceuticals, KalVista Pharma, Pharming, Pharvaris, Takeda, WSIB; has received speaker\u2019s honoraria from CSL Behring, Biocryst Pharmaceuticals, Novartis, and Takeda; and has received research funding from the Canadian Institutes of Health Research (CIHR), the Canadian Immunization Research Network (CIRN), CSL Behring, and Takeda; BY, MFD, NT, RES: are employees of Cencora, Innomar Strategies, Inc; MM, HM, AM: are employees of CSL Behring Canada Inc.; SW: has received grants and research support from AllerGen, the Canadian Allergy, Asthma, and Immunology Foundation (CAAIF), and ALK-Abell\u00f3; speaker\u2019s bureau\/honoraria and consulting fees from GSK, Merck & Co. Canada, Novartis, CSL Behring, Pfizer Canada, Sanofi Canada, AZ, Takeda, Teva, Pediapharma (Medexus), Mylan, AbbVie, Sanofi, Aimmune, Regeneron, Aralez (Miravohealth), Bausch Lomb, Avir Pharma; serves on the Scientific Advisory Committee on Respiratory and Allergy Therapies (Health Canada), with Food Allergy Canada, Asthma Canada, board of directors with CHAEN, and the Allergy Asthma & Immunology Society of Ontario (AAISO).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}